Novel loss-of-function variants in CDC14A are associated with recessive sensorineural hearing loss in Iranian and Pakistani patients by Doll, J. et al.
 International Journal of 
Molecular Sciences
Article
Novel Loss-of-Function Variants in CDC14A are
Associated with Recessive Sensorineural Hearing
Loss in Iranian and Pakistani Patients
Julia Doll 1, Susanne Kolb 1, Linda Schnapp 1, Aboulfazl Rad 2,3 , Franz Rüschendorf 4,
Imran Khan 5, Abolfazl Adli 2, Atefeh Hasanzadeh 2, Daniel Liedtke 1 , Sabine Knaup 1,
Michaela AH Hofrichter 1, Tobias Müller 6, Marcus Dittrich 1,6, Il-Keun Kong 7 ,
Hyung-Goo Kim 8, Thomas Haaf 1 and Barbara Vona 1,3,*
1 Institute of Human Genetics, Julius Maximilians University, 97074 Würzburg, Germany;
julia.doll@uni-wuerzburg.de (J.D.); susi_kolb@yahoo.de (S.K.); schnapp-linda@web.de (L.S.);
liedtke@biozentrum.uni-wuerzburg.de (D.L.); sabine.knaup@uni-wuerzburg.de (S.K.);
michaela.hofrichter@uni-wuerzburg.de (M.A.H.); marcus.dittrich@biozentrum.uni-wuerzburg.de (M.D.);
thomas.haaf@uni-wuerzburg.de (T.H.)
2 Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar 009851, Iran;
rad6790@yahoo.com (A.R.); abolfazl_adli@yahoo.com (A.A.); atefeh.hasanzadeh5@gmail.com (A.H.)
3 Tübingen Hearing Research Centre, Department of Otorhinolaryngology, Head and Neck Surgery, Eberhard
Karls University, 72076 Tübingen, Germany
4 Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany;
fruesch@mdc-berlin.de
5 Department of Chemistry, Bacha Khan University, Charsadda, Khyber Pakhtunkhawa 24420, Pakistan;
imrangnu@gmail.com
6 Institute of Bioinformatics, Julius Maximilians University, 97074 Würzburg, Germany;
tobias.mueller@uni-wuerzburg.de
7 Department of Animal Science, Division of Applied Life Science (BK21plus), Institute of Agriculture and Life
Science, Gyeongsang National University, Jinju 52828, Korea; ikong7900@gmail.com
8 Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University,
Doha 34110, Qatar; hkim@hbku.edu.qa
* Correspondence: barbara.vona@uni-tuebingen.de; Tel.: +49-7071-29-88154
Received: 12 December 2019; Accepted: 31 December 2019; Published: 2 January 2020


Abstract: CDC14A encodes the Cell Division Cycle 14A protein and has been associated with autosomal
recessive non-syndromic hearing loss (DFNB32), as well as hearing impairment and infertile male
syndrome (HIIMS) since 2016. To date, only nine variants have been associated in patients whose
initial symptoms included moderate-to-profound hearing impairment. Exome analysis of Iranian and
Pakistani probands who both showed bilateral, sensorineural hearing loss revealed a novel splice
site variant (c.1421+2T>C, p.?) that disrupts the splice donor site and a novel frameshift variant
(c.1041dup, p.Ser348Glnfs*2) in the gene CDC14A, respectively. To evaluate the pathogenicity of both
loss-of-function variants, we analyzed the effects of both variants on the RNA-level. The splice variant
was characterized using a minigene assay. Altered expression levels due to the c.1041dup variant were
assessed using RT-qPCR. In summary, cDNA analysis confirmed that the c.1421+2T>C variant activates
a cryptic splice site, resulting in a truncated transcript (c.1414_1421del, p.Val472Leufs*20) and the
c.1041dup variant results in a defective transcript that is likely degraded by nonsense-mediated mRNA
decay. The present study functionally characterizes two variants and provides further confirmatory
evidence that CDC14A is associated with a rare form of hereditary hearing loss.
Keywords: CDC14A; DFNB32; autosomal recessive hearing loss; exome sequencing; splicing;
frameshift; non-sense mediated mRNA decay
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1. Introduction
Hearing loss (HL) is a highly heterogeneous disorder and belongs to one of the most common
sensory disorders in humans with a prevalence of 1–2 in 1000 newborns. Approximately 120 genes
responsible for non-syndromic HL have been identified so far [1,2]. Since 2016, the gene CDC14A
(OMIM: *603504, ENSG00000079335) has been associated with autosomal recessive non-syndromic
deafness-32 (DFNB32, OMIM: #608653) [3]. Two years later, it was recognized as causing hearing
impairment and infertile male syndrome (HIIMS) [4]. CDC14A is located on chromosome 1p21.2 and
encodes an evolutionarily conserved protein tyrosine phosphatase (Cell Division Cycle 14A) that is
important for centrosome separation and productive cytokinesis during cell division [5]. It is present in
the kinocilia of hair cells, as well as basal bodies and sound-transducing stereocilia of the mouse inner
ear [3]. Homozygous Cdc14a mutant mice showed postnatal degeneration of hair cells but normal
length kinocilia. Additionally, degeneration of seminiferous tubules and spermiation defects resulted
in infertile male mice [4]. Alternative splicing of CDC14A yields six different transcripts, with the
largest protein encoding 623 amino acids [3]. To date, only nine homozygous genetic variants in 10
different families with a Middle Eastern background have been associated with hearing impairment
(Table 1). Five of these variants with one additional presumed variant also caused male infertility [3,4].
Patients with biallelic CDC14A variants present variable degrees of HL that range from moderate to
profound in severity [4].
Exome sequencing and gene mapping approaches revealed a homozygous splice variant in a
22.5 Mb homozygous interval on chromosome 1 in two hearing impaired patients from an Iranian
family (family 1). Additionally, a homozygous frameshift variant in a 13.6 Mb homozygous interval on
chromosome 1 was identified in two Pakistani patients (family 2). Both families had a consanguineous
background and both genetic variants were novel. We subsequently evaluated the functional effects of
the two variants by assessing aberrant splicing and abnormal gene expression. Our findings widen the
spectrum of clinically relevant CDC14A mutations that are associated with hearing impairment and
reinforce its role within the auditory system.
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Table 1. Summary of previously described and newly identified families with homozygous variants in CDC14A.
Family ID Variant Sex HL Onset HL Severity Male Infertility Ethnicity Reference
HLRB11 c.376delTp.Tyr126Ilefs*64
Male
Female Congenital
moderate-to-profound,
progressive Yes Pakistani Imtiaz et al. [4]
HLAI24 c.417C>Gp.Tyr139Ter
Male
Female Congenital
moderate-to-profound,
progressive Yes Pakistani Imtiaz et al. [4]
FT1 c.935G>Ap.Arg312Gln
Male
Female Congenital
moderate-to-severe,
progressive n.a. Tunisian Imtiaz et al. [4]
HPK1 c.839-3C>Gp.? Male Congenital
moderate-to-profound,
progressive Yes Pakistani Imtiaz et al. [4]
MORL1 c.934C>Gp.Arg312Gly
Male
Female Congenital
severe-to-profound,
progressive Yes Iranian Imtiaz et al. [4]
PKDF539 c.959A>Cp.Gln320Pro Male Congenital
severe-to-profound,
progressive Yes Pakistani Imtiaz et al. [4]
Mauritanian family c.1015C>Tp.Arg339Ter Male Congenital Profound No Mauritanian Delmaghani et al. [3]
PKSN10 c.1033C>Tp.Arg345Ter
Male
Female Congenital
moderate-to-profound,
progressive No Pakistani Imtiaz et al. [4]
MORL2 c.1126C>Tp.Arg376Ter
Male
Female Congenital moderate-to-profound No Iranian Imtiaz et al. [4]
Iranian family c.1126C>Tp.Arg376Ter
Male
Female Congenital severe-to-profound No Iranian Delmaghani et al. [3]
Family 1 c.1421+2T>Cp.Val472Leufs*20 Female Congenital severe-to-profound No Iranian Present study
Family 2 c.1041dupp.Ser348Glnfs*2 Male Congenital Profound n.a. Pakistani Present study
Abbreviations: n.a., not available.
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2. Results
2.1. Clinical Presentation
All patients reported congenital, bilateral, sensorineural HL (Figure 1). The affected individuals
in family 1 reported severe-to-profound HL (II.2 (asymmetrical HL, age 43), II.8; Figure 1a,c), whereas
the affected individuals in family 2 (II.1 (age 29), II.2 (age 27)) showed profound HL (Figure 1b,d). A
diagnosis of clinical HL of the older sibling in family 2 (II.2) was secured at 1 year of age after his
mother recognized signs of hearing impairment. However, HL was suspected since birth and was the
case with his younger sibling. Furthermore, the HL in the proband of family 1 can be described as
non-progressive. Information about progression is unavailable from the affected individuals in family
2. There were no complaints of vestibular dysfunction or tinnitus in the affected individuals of family
2. The ophthalmic examination of family 1 was normal apart from mild refractive error. In addition to
HL, the affected individuals in family 2 (II.1, II.2) suffer from compound myopic astigmatism. Both
affected individuals in family 2 (II.1, II.2) are unmarried and have no children.
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Figure 1. Pedigree, segregation of the CDC14A variants in families 1 and 2 and pure-tone 
audiometry. (a,b) An Iranian ((a) family 1) and Pakistani family ((b) family 2) with a consanguineous 
background, each showing two affected individuals ((a), II.2, II.8; (b) II.1, II.2) who are shown in 
black symbols. Unaffected parents and siblings are shown in white symbols. The probands are 
marked with arrows. The mutated allele is marked with a “-”. The wild type allele is displayed with a 
“+”. Sanger sequence chromatograms of the CDC14A c.1421+2T>C variant in wild type (WT; (a), left) 
and homozygous ((a), right) orientation and the CDC14A c.1041dup variant in heterozygous ((b), 
left) and homozygous ((b), right) orientation. (c,d) Audiograms showing pure-tone air conduction 
thresholds of II.2 ((c), family 1) and II.1, II.2 ((d), family 2). Air conduction thresholds for right and 
left ears are represented with circles and crosses, respectively. Abbreviations: het, heterozygous; 
hom, homozygous; wt, wild type. 
2.2. Identification of Two Novel CDC14A Variants 
Exome sequencing and bioinformatics analysis of 174 HL-associated genes (Supplementary 
Table S1) ensued using the genomic DNA of the probands of each family. The proband from family 1 
(II.2) revealed a homozygous CDC14A (NCBI Reference Sequence: NM_033312.2) splice variant 
c.1421+2T>C that abolished the donor splice site in intron 14 out of 15 encoded exons and was 
consistent with segregation analysis within family 1 (Figure 1a). Both affected individuals II.2 and 
II.8 were homozygous for the c.1421+2T>C variant, while an unaffected brother (II.3) was wild type 
(WT). A homozygous frameshift variant c.1041dup (p.Ser348Glnfs*) in exon 11 out of 15 exons was 
detected in the proband from family 2 (II.1) after exome sequencing and bioinformatics analysis, 
Figure 1. Pedigree, segregation of the CDC14A variants i families 1 and 2 and pure-tone audiometry.
(a,b) An Iranian ((a) family 1) and Pakistani family ((b) family 2) with a consanguineous background,
each showing two affected individuals ((a), II.2, II.8; (b) II.1, II.2) who are shown in black symbols.
Unaffected parents and siblings are shown in white symbols. The probands are marked with arrows.
The mutated allele i mark d with a “-”. The wild type allele is displayed with a “+”. Sanger sequence
chromatograms of the CDC14A c.1421+2T>C variant in wild type (WT; (a), left) and homozygous
((a), right) orientation and the CDC14A c.1041dup variant in heterozygous ((b), left) and homozygous
((b), right) orientation. (c,d) Audiograms showing pure-tone air conduction thresholds of II.2 ((c), family
1) and II.1, II.2 ((d), family 2). Air conduction thresholds for right and left ears are represented with
circles and crosses, respectively. Abbreviations: het, heterozygous; hom, homozygous; wt, wild type.
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2.2. Identification of Two Novel CDC14A Variants
Exome sequencing and bioinformatics analysis of 174 HL-associated genes (Supplementary
Table S1) ensued using the genomic DNA of the probands of each family. The proband from family
1 (II.2) revealed a homozygous CDC14A (NCBI Reference Sequence: NM_033312.2) splice variant
c.1421+2T>C that abolished the donor splice site in intron 14 out of 15 encoded exons and was
consistent with segregation analysis within family 1 (Figure 1a). Both affected individuals II.2 and
II.8 were homozygous for the c.1421+2T>C variant, while an unaffected brother (II.3) was wild type
(WT). A homozygous frameshift variant c.1041dup (p.Ser348Glnfs*) in exon 11 out of 15 exons was
detected in the proband from family 2 (II.1) after exome sequencing and bioinformatics analysis,
which also co-segregated within family 2 (Figure 1b). The affected individuals II.1 and II.2 were
homozygous for the c.1041dup, while the mother (I.2) and unaffected brother (II.3) were heterozygous.
Both variants were absent from all applied population databases. All other variants that were identified
by bioinformatics analysis of the in silico gene panel were prioritized as benign or could not explain
the HL phenotype. Bioinformatic screening of the gene CDC14A in our in-house exome database that
includes approximately 330 individuals with HL did not reveal additional potentially pathogenic
variants. Copy number variations were excluded in the 174 HL-associated genes.
Homozygosity mapping disclosed a 22.5 Mb (chr1: 89,845,926-112,389,040; all subsequent
coordinates reported in GRCh37) homozygous interval on chromosome 1 including the CDC14A gene
(coordinates chr1: 100,810,598-100,985,833) in the Iranian proband (II.2, family 1). The Pakistani family
2 was genotyped with a genome-wide SNP array and homozygosity mapping, identical by descent
(IBD), with linkage analysis revealed 15 regions reaching the maximal logarithm of the odds (LOD)
score of 1.927. The longest region (chr1: 88,430,037-102,069,696) of 13.6 Mb spans the CDC14A gene.
According to four out of five in silico prediction tools (MaxEntScan, NNSplice, GeneSplicer
and Human Splicing Finder; Alamut visual, version 2.10), the homozygous c.1421+2T>C variant is
predicted to disrupt the exon 14 to intron 14/15 splice donor site (Figure 2d). That loss would likely
mediate exon skipping or the use of an alternative cryptic splice site nearby. The duplication c.1041dup
(p.Ser348Glnfs*2) in family 2 leads to a frameshift and the incorporation of a premature stop codon
two triplicate bp positions downstream.
2.3. Functional Characterization of the Splice Variant c.1421+2T>C
The effect of the splice variant (c.1421+2T>C) in intron 14 was subjected to testing using a minigene
assay that included cloning of exon 14, as well as the 5′ and 3′ flanking intronic sequences into an
exon trapping vector (Figure 2a). PCR amplification and Sanger sequencing of WT and mutant cDNA
revealed two products of different sizes (Figure 2b,c) that is the result of a truncation of eight nucleotides
(GTAAGAAG) in the mutated sequence (372 bp) compared to the WT control (380 bp) due to activation
of a cryptic splice site in exon 14 (Figure 2d). The 257 bp sequence in the empty vector control appeared
as expected. The eight nucleotide deletion leads to a frameshift c.1414_1421del, p.Val472Leufs*20
(NM_033312.2) and the incorporation of a premature stop codon 20 triplicate bp positions downstream
(Figure 2e). Assuming that a protein is translated, it is expected that the full protein would be truncated
by approximately 21%.
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Figure 2. Characterization of the CDC14A c.1421+2T>C exchange via a minigene assay. (a) A 
schematic of the pSPL3 exon trapping vector with cloned CDC14A exon 14 (blue) and flanking 
sequence containing XhoI and BamHI restriction sites that was directly amplified from proband and 
wild type genomic DNA. Exons A and B (purple) originate from the vector. A schematic of the 
resulting splice products is shown, with the wild type splicing profile (top) and splice variant 
sequence that activates a cryptic splice site (bottom, red asterisk). The PCR primers that were used to 
amplify the Exon A splice donor region (SD6) and Exon B splice acceptor region (SA2) are depicted 
by green arrows. (b) Electrophoretic visualization of cDNA RT-PCR products amplified from 
constructs after transfection into HEK293T cells. Amplicons were resolved on a 1% agarose gel. Wild 
type splicing (lane: pSPL3 CDC14A WT) yields a 380 bp product that constitutes the Exon A, exon 14 
and Exon B amplified regions. The homozygous mutant amplicon (lane: pSPL3 CDC14A hom) shows 
a band around 380 bp that, when sequenced, indicates a cryptic splice site activation. The empty 
vector shows the expected 257 bp product. (c) Sequencing electropherograms of the exon 14 5′ splice 
site boundaries for the RT-PCR products for wild type (top), mutant showing cryptic splice site 
activation (middle) and empty vector (bottom). (d) In silico splice prediction tools for the 
c.1421+2T>C exchange that is marked with red lines visualized with Alamut visual (2.10). The upper 
panel shows the reference sequence splice scores and the lower panel shows the splice scores for the 
c.1421+2T>C exchange with multiple in silico prediction tools estimating the loss of the native exon 
Figure 2. Cha acteriz tion of he CDC14A c. 421+2T>C exchange via minigene ass . schematic
of the pSPL3 exon trapping vector with cloned CDC14A exon 14 (blue) and flanking sequence containing
XhoI and BamHI restriction sites that was directly amplified from proband and wild type genomic DNA.
Exons A and B (purple) originate from the vector. A schematic of the resulting splice products is shown,
with the wild type splic ng profile (top) and splice vari nt sequence that activates a cryptic splice site
(bottom, red asterisk). The PCR primers that were used to amplify the Exon A splice donor region (SD6)
and Exon B splice acceptor region (SA2) are depicted by green arrows. (b) Electrophoretic visualization
of cDNA RT-PCR products amplified from constructs after transfection into HEK293T cells. Amplicons
were resolved a 1% aga ose gel. Wild t pe splicing (lane: pSPL3 CDC14A WT) yields a 380 bp
product that constitutes the Exon A, exon 14 and Exon B am lified regions. The homozygous mutant
amplicon (lane: pSPL3 CDC14A hom) shows a band around 380 bp that, when sequenced, indicates a
cryptic splice site activation. The empty vector shows the expected 257 bp product. (c) Sequencing
electropherograms of the exon 14 5′ splice site boundaries for the RT-PCR products for wild type (top),
mutant showing cryptic splice ite activation (middle) and mpty vector (bottom). (d) In silico splice
prediction tools for the c.1421+2T>C exchange that is marked with red lines visualized with Alamut
visual (2.10). The upper panel shows the reference sequence splice scores and the lower panel shows
the splice scores for the c.1421+2T>C exchange with multiple in silico prediction tools estimating the
loss of the native exon 14 5′ donor splice site that is due to the variant (shown with a black box). In the
mutant panel, the splice scores of an adjacent cryptic 5′ donor site are either unchanged or strengthened
and marked with a black arrow. (e) Effect of the splice variant on the protein, comparing wild type
(top) and the truncated (bottom) protein resulting from the aberrantly spliced product (visualized with
Mutalyzer). The amino acid residues marked in red are those that are altered due to the variant.
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2.4. Quantification of Relative Expression Levels for CDC14A
To investigate whether the premature termination codon (PTC) induced by the c.1041dup
(p.Ser348Glnfs*2) variant triggers nonsense-mediated mRNA decay (NMD) of CDC14A in family 2,
we quantified relative CDC14A mRNA expression. RT-qPCR was performed utilizing whole blood of
homozygous (II.2) and heterozygous (I.2) individuals with two different primer pairs targeting a region
at the anterior part of the gene (exon 2–3, NM_033312.2) and a region posterior to the frameshift variant
in exon 11 (exon 11–12, NM_033312.2). The RT-qPCR analysis showed that the relative expression levels
of CDC14A were significantly reduced by approximately 99% relative expression for both targeted
regions for the homozygous individual (II.2) relative to WT controls. We could observe a difference of
17%–34% (exon 2–3) and approximately 57% (exon 11–12) relative expression for the heterozygous
individual I.2 when compared relative to WT controls (Figure 3a). In principle, the introduction of
a PTC directly after p.348 would truncate 44% of the amino acid residues in full length CDC14A
(Figure 3b).
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variant in homozygous, heterozygous and wild type control individuals. (a) Relative expression 
levels are shown for exon 2–3 (F(4, 10) = 150.69) and exon 11–12 (F(4, 10) = 112.84) for the normalized 
reference samples (wt controls 1, 2 and 3), and both tested individuals in family 2 (I.2, heterozygous 
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Figure 3. Quantification of the RT-qPCR relative expression values for the CDC14A c.1041dup variant
in homozygous, heterozygous and wild type control individuals. (a) Relative expression levels are
shown for exon 2–3 (F(4, 10) = 150.69) and exon 11–12 (F(4, 10) = 112.84) for the normalized reference
samples (wt controls 1, 2 and 3), and both tested individuals in family 2 (I.2, heterozygous for c.1041dup
and II.2, homozygous for c.1041dup). N = 3 for each group. Values are represented as means and
error bars extend to the respective minimal and maximal values. To improve readability, significant
differences are only indicated for pairwise comparisons to the normalized reference sample (wt control
1). See Supplementary Table S2 for extended information. * p < 0.05 and *** p < 0.001. (b) Effect of
the c.1041dup variant on the protein, comparing wild type (top) and the truncated (bottom) protein
resulting from the aberrantly spliced product (visualized with Mutalyzer). The amino acid residues
marked in red are those that are altered due to the variant.
Both variants have been submitted to LOVD v 3.0 under the accession IDs 00269609 and 00269610.
3. Discussion
The CDC14A gene encodes a protein that is a member of the highly conserved dual specificity
protein-tyrosine phosphatase family existing in a wide range of organisms from yeast to human [6].
Their ability to dephosphorylate serine, threonine, as well as tyrosine residues of different proteins
is required for the regulation of essential signaling pathways and biological processes such as
protein–protein interactions, cell-cycle progression or apoptosis [7]. The encoded protein CDC14A is
thought to be involved in the conservation of hair cells in mice and is essential both for normal hearing
and male fertility in humans according to nine previously described mutations [3,4]. Furthermore,
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in mice, CDC14A appears to be advantageous for perinatal survival [4]. The paralogue CDC14B
may compensate for the loss of some CDC14A functions in vivo, but does not compensate for male
infertility and hearing impairment with loss of CDC14A [4].
Interestingly, there is a noticeable accumulation of pathogenic variants that are responsible for
a distinct hearing impaired phenotype in exon 11 (NM_033312.2) and variants that are responsible
for HIIMS in exon 10, containing the core dual-specificity phosphatase domain (DSPc/PTPc;
Figure 4). Patients who have thus far been identified with C-terminal truncating variants have
moderate-to-profound hearing impairment and males with apparently normal fertility, whereas
patients with truncating variants in exons encoding two protein domains (exon 10 encodes part of the
DSPc/PTPc domain and exons 5 and 6 encode the dual-specificity phosphatase domain (DSPn)) have
HIIMS that includes moderate-to-profound hearing impairment (Figure 4, Table 1). It is thought that
transcripts with truncating mutations in exon 11 probably avoid NMD since a short isoform containing
only 11 exons (NM_003672) also exists compared to the longest isoform (NM_0033312.2) that has 15
exons [4].
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of 15 exons. The dual-specificity phosphatase dom in (DSPn) and the core dual-sp cificity phosphatase
domain (DSPc/PTPc) are represent d in green a d blue bars, r spectively. Indicate ar the nine
previously d scribed mutat ons (above) and the two newly identified variants in the affected individuals
from family 1 and 2 (red, below). The two different phenotypes are indicated with a circle (hearing
impairment and male infertility) or triangle (NSHL).
The congenital, sensorineural HL phenotype in our patients that ranged from severe-to-profound
in the Iranian family (family 1) and profound in the Pakistani family (family 2) can be compared to
already presented HL patients with mutations in CDC14A that showed prelingual severe-to-profound
deafness (Table 1) [3]. Most of the families with autosomal recessive non-syndromic hearing loss
(ARNSHL) come from the ‘consanguinity belt’ that includes regions of North Africa, the Middle East
and India and uncovered unique signatures of variants in the past [8]. All previously described variants
in CDC14A were found in families originating from this specific region such as Pakistan, Iran, Tunisia
and Mauritania and show a comparable ethnicity as the two families (Iranian and Pakistani) presented
in this study.
In contrast to some of the already described HIIMS patients that showed signs of progressive
moderate-to-profound HL [4], progression was unreported in our families. Since both affected
individuals in family 1 are female and the unmarried status of both affected males in family 2, we
cannot exclude that the newly identified CDC14A variants would also cause male infertility.
The process of RNA splicing is an essential post-transcriptional mechanism ensuring the correct
junction of neighboring exons by the removal of intermediate intronic sequences through the
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spliceosome complex [9]. Sequence variants in regions critical for correct splicing can consequently
lead to exon-skipping or the activation of cryptic splice sites and are responsible for a variety of
different diseases [10]. Cryptic splice sites are normally repressed by stronger splice sites that are
located nearby, competing for selection by the splicing machinery [11]. One possible consequence of
the splice variant c.1421+2T>C in family 1 that is located in intron 14 was exon skipping of exon 14
due to a disruption and consequently weakening of the splice donor site. We verified the activation
of an alternative cryptic splice site located eight base pairs upstream within exon 14 (Figure 2d) that
results in a frameshift and a truncated protein (p.Val472Leufs*20; Figure 2e) instead of exon skipping
and postulate that this variant is responsible for the hearing impaired phenotype within this family.
The vital process of eukaryotic gene expression such as transcription, translation and degradation
of mRNA and proteins is essential to ensure a functional gene product [12]. There are several different
pathways that are involved in the decay of defectively transcribed gene products most often starting
with poly(A) shortening by the Ccr4-Not deadenylase complex followed by either 5′ end decapping
(Dcp1/2) and Xrn1 mediated decay [13] or 3′ end exonucleolytic decay mediated by an exosome [14].
Frameshift or nonsense mutations are often responsible for NMD, a crucial process that prevents the
production of truncated or potentially toxic dominant-negative proteins [15]. The c.1041dup frameshift
variant in family 2 is responsible for the incorporation of a premature stop-codon likely resulting
in a truncated transcript. If translated, over >40% of the transcript would be missing that is likely
degraded by NMD. We could confirm significantly decreased relative CDC14A expression levels for
both the unaffected heterozygous and the affected homozygous individual including both the anterior
and the posterior part of the mRNA transcript (Figure 3a). Since we only investigated total mRNA
levels isolated from whole blood, targeting distinct transcripts of the CDC14A gene, we cannot rule
out the possibility of compensatory mechanisms such as upregulation of different gene transcripts in
other human tissues [16]. Nevertheless, we have experimentally shown that the truncated CDC14A
product by the c.1041dup frameshift variant is likely targeted by the mechanism of NMD resulting in
insufficient levels of functional transcript for the homozygous proband (Figure 3).
Both variants are anticipated to produce a loss-of-function, either through possible truncated
protein from the c.1421+2T>C variant, or NMD that is anticipated to occur as a result of the
c.1041dup variant.
In order to distinguish between a regular stop codon and a PTC, the NMD machinery recognizes
the position of the PTC within newly produced mRNAs. If the PTC is located at least 50–55 nucleotides
upstream of the 3′-most exon–exon junction, degradation by the NMD machinery is likely induced
to avoid unfavorable transcripts [17]. Since the PTC of the CDC14A frameshift variant c.1041dup is
located in exon 11 and is followed by a 3′ exon–exon junction more than 55 nucleotides downstream,
NMD is likely triggered. Our results showing reduced relative expression levels for CDC14A in
patients also confirmed this hypothesis. The PTC that originates from the aberrantly spliced transcript
(p.Val472Leufs*20) due to the c.1421+2T>C variant is located in the last exon (exon 15) of CDC14A.
Since there is no 3′ exon–exon junction further downstream of the PTC, a transcript is likely produced
to subsequently escape the NMD machinery.
4. Materials and Methods
4.1. Patient Recruitment and Clinical Assessment
Informed written consent was obtained from the families. This study was performed under the
tenets of the Declaration of Helsinki and was approved by the Ethics Commission of the University of
Würzburg (46/15, approval date: 31 March 2015).
We recruited an Iranian (family 1) and Pakistani (family 2) family who both showed a history of
parental consanguinity for a total of four affected individuals, as well as unaffected parents and siblings
(Figure 1a,b). The affected individuals (family 1: II.2, II.8; family 2: II.1, II.2) underwent audiological
assessment and were tested by pure-tone audiometry adhering to recommendations described in
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Mazzoli et al. (2003) [18]. Ophthalmic examination of the proband in family 1, as well as both affected
individuals from family 2 was performed.
4.2. Exome Sequencing
Genomic DNA (gDNA) from the two affected individuals was extracted from whole blood.
Diagnostic screening of GJB2, the most frequently implicated gene in non-syndromic hearing loss,
excluded putative pathogenic variants. gDNA of the probands were exome sequenced. Exome library
preparation was performed with the TruSeq Exome Enrichment (family 1) and the Nextera Rapid
Capture Exome (family 2) kits (Illumina, San Diego, CA, USA) according to manufacturer’s instructions
and paired-end sequenced (2 × 76 bp) with the NextSeq500 sequencer (Illumina, San Diego, CA, USA).
A v2 high output reagent kit (Illumina) was used and the data were aligned to the human reference
genome GRCh37 (hg19).
4.3. In Silico Variant Analysis
Data analysis was performed with GensearchNGS software (PhenoSystems SA, Wallonia,
Belgium) and an in-house bioinformatics pipeline. Variant filtering was done with a minor allele
frequency <0.01 and alternate allele present at >20%. The pipeline data were analyzed based on the
GATK toolkit [19] and BWA based read alignment to the human genome (hg19) following GATK
best practice recommendations [20,21]. Quality filtering was performed based on the VQSLOD
score. Data from the Greater Middle East Variome Project [22], the Iranome Database [23] and
gnomAD [24] were used for population-specific filtering. Variant analysis was done with the use
of PolyPhen-2 [25], SIFT [26] and MutationTaster [27], as well as variant information annotated in
the Deafness Variation Database (DVD) [28]. Exome CNV analysis was performed using the eXome
Hidden MarkovModel (XHMM, version 1.0) approach [29]. Splice-site variants were classified on the
basis of in-silico splice predictors such as SpliceSiteFinder-like [30], MaxEntScan [31], NNSPLICE [32],
Genesplicer [33] and Human Splicing Finder [34]. Homozygosity mapping was done and visualized
with HomozygosityMapper [35]. Mutalyzer was used to assess the effect of the variants on the protein
in silico [36].
4.4. Gene Mapping Approaches
The exome data of the proband from family 1 was subjected to homozygosity mapping that was
performed using HomozygosityMapper [35]. The gDNA from individuals (I.2, II.1, II.2, II.3) from
family 2 were subjected to genome-wide genotyping using the Infinium HumanCore-24 v1.0 Bead
Chip (Illumina) using manufacturer’s protocols.
Data conversion to linkage format files and quality control (QC) was managed with ALOHOMORA
software [37]. Up to 258,000 biallelic SNPs after QC were used for linkage analysis with Merlin [38].
Linkage analysis was done with a recessive genetic model with complete penetrance, a rare disease
allele frequency of 0.001 and a pedigree with a consanguinity loop (cousin marriage of parents I.1 and
I.2). As genetic coordinates, we used the physical position (1 cM⇔ 1 Mb, hg19). Linkage regions where
the LOD score reached the maximal value of 1.927 for this family, indicate homozygous (autozygous)
stretches for the two affected individuals (II.1 and II.2) and where the unaffected brother (II.3) is not
homozygous. Linkage analysis was repeated with a linkage disequilibrium (LD) reduced marker set to
verify that LOD score peaks are not inflated by LD.
Genomic coordinates are reported using the GRCh37 human genome assembly.
4.5. Validation of The CDC14A Variants and Segregation Analysis
Validation of the CDC14A frameshift and splice variants was carried out by Sanger
sequencing from PCR-amplified gDNA from the probands and available family members
using standard cycling conditions and primers (F: 5′-TCCGCAAAGATTAAGTTCATCCC-3′
and R: 5′-TCTGGATCACACTAAGCCAGC-3′) to validate the c.1421+2T>C and (F:
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5′-CTGAGGACTTCAGCAGTCAA-3′ and R: 5′-AACTTGGTACTCGTGGCATC-3′) c.1041dup
variants (Metabion, Martinsried, Germany). Primers were designed with Primer3 [39]. The amplicons
were sequenced with an ABI 3130xl 16-capillary sequencer (Life Technologies, Carlsbad, CA, USA)
and the data were analyzed with Gensearch 4.3 software (PhenoSystems SA, Wallonia, Belgium).
4.6. Minigene Assay
To test the in silico splice predictions, an in vitro splicing assay was carried out using a modified
protocol from Tompson and Young [40]. Briefly, wild-type and mutant CDC14A exon 14 (123 bp)
were directly PCR amplified from a control individual and the proband with specific primers
containing an additional XhoI and BamHI restriction site (forward primer with XhoI restriction
site: 5′-aattctcgagCCGCTGCTGTCATCACTATTA-3′ and reverse primer with BamHI restriction site:
5′-attggatccACCATTCCCTCCACAACCTT-3′). The PCR reaction amplified the entire exon 14 sequence
plus an additional 133 bp (5′) and 193 bp (3′) from the flanking intronic regions. After PCR amplification,
PCR clean-up, restriction enzyme digestion of the PCR fragments and pSPL3 exon trapping vector
was performed prior to cloning of exon A and exon B fragments into the linearized pSPL3-vector
and DH5α competent cells (NEB 5-alpha, New England Biolabs, Ipswich, MA, USA. The WT and
mutant-containing vector sequences were Sanger sequence confirmed.
Vectors containing either homozygous or WT sequence were transfected into HEK 293T cells
(ATCC) at a density of 2 × 105 cells per mL. Of the respective pSPL3 vector 2 µg was transiently
transfected using 6 µL of FuGENE 6 Transfection Reagent (Promega, Madison, WI, USA. An empty
vector and negative transfection reactions were included as controls. The transfected cells were
harvested 24 h after transfection for RNA extraction. Total RNA was prepared using miRNAeasy
Mini Kit (Qiagen, Venlo, Netherlands). Approximately 1 µg of RNA was reverse transcribed
using a High Capacity RNA-to-cDNA Kit (Applied Biosystems, Waltham, MA, USA) following
the manufacturer’s protocols. The cDNA was PCR amplified using vector-specific SD6 forward
(5′-TCTGAGTCACCTGGACAACC-3′) and reverse SA2 (5′-ATCTCAGTGGTATTTGTGAGC-3′)
primers. The amplified fragments were visualized on a 1% agarose gel and subsequently
Sanger sequenced.
4.7. Expression Analysis Using Reverse Transcription Quantitative Real-Time PCR (RT-qPCR)
To examine altered expression levels in CDC14A due to the loss-of-function variant in family 2,
total RNA was extracted from whole blood of probands I.2 and II.2 (family 2) using PAXgene Blood
RNA Kit (Qiagen) according to manufacturer’s instructions. cDNA was synthesized using High
Capacity RNA-to-cDNA Kit (Applied Biosystems). We performed RT-qPCR using a ViiA7 Real-Time
PCR System (Thermo Fisher Scientific, Waltham, MA, USA). Each sample and primer pair was analyzed
in triplicates on a single qPCR plate using HOT FIRE Pol Eva Green Mix Plus (Solis BioDyne, Tartu,
Estonia). Relative expression levels were calculated using the QuantStudio Real-Time PCS Software
v1.3 by ∆∆Ct method. Control samples were either used as reference samples or for relative expression
comparison. Combined cT values of housekeeping genes GAPDH, IPO8 and HPRT1 were used for
endogenous cDNA controls. Used primer pairs are listed in Table 2.
Table 2. Primer sequences for RT-qPCR.
Exon 5′-3′ Primer Sequence (Forward) 5′-3′ Primer Sequence (Reverse)
CDC14A Ex2_3 CCCACTATTTCTCCATCGATGA GTACACCATTGCCAAGTTCAG
CDC14A Ex11_12 TGGCCTAGATGATATGTCTATTG CTTCTAAGTTATCCTCTCCAAATC
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
IPO8 CGAGCTAGATCTTGCTGGGT CGCTAATTCAACGGCATTTCTT
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
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4.8. Statistical Data Collection
The results of RT-qPCR are represented as relative quantification (RQ) means. Statistical analysis
was performed using OriginPro 2018G. Normality (Shapiro–Wilk) and equality of variances (Levene’s)
were calculated and a one-way ANOVA with Bonferroni correction for multiple comparisons was
subsequently conducted. A p-value of less than 0.05 is considered statistically significant.
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